OneMedNet Corporation announced the next phase of its iRWD™ Real‑World Data platform, powered by Palantir Foundry, on February 27, 2026. The update follows a November 10, 2025 demonstration that showcased live data feeds, subscription access, and AI‑driven search at major tradeshows, and signals the company’s active conversion of customer evaluations into commercial subscriptions.
The iRWD™ platform now draws on a network of more than 2,130 healthcare sites, providing regulatory‑grade, AI‑ready data with real‑time access. The partnership with Palantir expands the network’s scale, diversity, and longitudinal depth, positioning OneMedNet to secure larger contracts and increase average deal size while accelerating the shift to a high‑margin recurring revenue model.
Financially, OneMedNet reported record 2025 bookings of $2.79 million, a 4.1‑fold increase over the prior year, but the company remains in negative profitability territory. Gross margin was –125.4 % and operating margin –1262.7 % in Q3 2025, and the current ratio stood at 0.19, indicating tight liquidity. The company has also faced Nasdaq compliance issues related to minimum bid price and market value of listed securities.
CEO Aaron Green emphasized the platform’s impact, stating, "Customer feedback has reinforced the platform’s performance, speed, and depth of discovery. We believe this traction validates our strategy of combining conversational AI‑driven search with scalable, prospective data feeds, strengthening customer confidence as we expand subscriptions and deliver fast, intuitive value for Real‑World evidence generation."
The announcement has drawn significant investor attention, reflecting optimism about the platform’s potential to transform data access for life‑sciences and AI developers, while highlighting the company’s ongoing financial challenges and regulatory compliance hurdles.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.